Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2018
Price : $35 *
At a glance
- Drugs GSK 2634673F (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Diagnostic use
- Acronyms PETAL
- Sponsors GlaxoSmithKline
- 17 Mar 2017 Status changed from completed to discontinued.
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.